CAMILLE LUCIA BEDROSIAN, MD
Osteopathic Medicine at Landsdowne St, Cambridge, MA
License number
Massachusetts 153940
Category
Osteopathic Medicine
Type
Internal Medicine
License number
Massachusetts 30889
Category
Osteopathic Medicine
Type
Internal Medicine
License number
Massachusetts 153940
Category
Osteopathic Medicine
Type
Hematology & Oncology
License number
Massachusetts 30889
Category
Osteopathic Medicine
Type
Hematology & Oncology
Address
Address
2
26 Landsdowne St, Cambridge, MA 02139
22 Lantern Rd, Belmont, MA 02478
22 Lantern Rd, Belmont, MA 02478
Phone
(617) 494-0400
(617) 494-8144 (Fax)
(617) 484-1182
(617) 494-8144 (Fax)
(617) 484-1182
Personal information
See more information about CAMILLE LUCIA BEDROSIAN at radaris.comName
Address
Phone
Belmont, MA
22 Lantern Rd, Belmont, MA 02478
Professional information
Camille Lucia Bedrosian, Cambridge MA
Specialties:
Internist
Address:
26 Landsdowne St, Cambridge, MA 02139
Education:
Harvard Medical School - Doctor of Medicine
Duke University Hospital - Fellowship - Hematology and Oncology (Internal Medicine)
Duke University Hospital - Residency - Internal Medicine
Duke University Hospital - Fellowship - Hematology and Oncology (Internal Medicine)
Duke University Hospital - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine
Biomarkers For Evaluating Likelihood Of Tumor Sensitivity To An Mtor Inhibitor
US Patent:
2009021, Aug 27, 2009
Filed:
May 8, 2006
Appl. No.:
11/913964
Inventors:
Camille L. Bedrosian - Belmont MA, US
Timothy P. Clackson - Lexington MA, US
Victor Rivera - Arlington MA, US
Timothy P. Clackson - Lexington MA, US
Victor Rivera - Arlington MA, US
Assignee:
ARIAD GENE THERAPEUTICS, INC. - Cambridge MA
International Classification:
A61K 31/436, C12Q 1/00, C12Q 1/68, G01N 33/53
US Classification:
514291, 435 4, 435 6, 435 71
Abstract:
The present invention provides compositions and methods for evaluating the likelihood that a tumor is sensitive to an mTOR inhibitor, e.g., rapamycin or a rapamycin analog. The invention provides FKBP proteins as biomarkers for predicting the likelihood that a tumor is sensitive to an mTOR inhibitor. The methods include assessing the expression or activity of an FKBP protein, e.g., FKBP 12, in a subject with a tumor or in a sample derived from a tumor. Additional biomarkers and biomarker combinations are also provided. The invention also provides kits containing, e.g., a validated antibody or ligand for assessing the expression or activity of an FKBP protein.
Therapeutic Materials And Methods
US Patent:
2006019, Aug 31, 2006
Filed:
Dec 20, 2005
Appl. No.:
11/312296
Inventors:
Timothy Clackson - Arlington MA, US
Camille Bedrosian - Belmont MA, US
Camille Bedrosian - Belmont MA, US
International Classification:
A61K 31/4745, A61K 31/4545, A61K 31/445
US Classification:
514291000, 514316000, 514317000
Abstract:
Disclosed are compositions and methods for treating or preventing mucositis by administering to the patient an FKBP ligand prior to, during, or after treatments commonly associated with the development of mucositis such as certain chemotherapies, radiation therapies, or combinations thereof, but in particular, administration of an mTOR inhibitor such as rapamycin, AP23573, CC1779 or everolimus.
Therapeutic Materials And Methods
US Patent:
2008020, Aug 28, 2008
Filed:
Nov 27, 2007
Appl. No.:
11/986878
Inventors:
Stephen T. Sonis - Wayland MA, US
Camille L. Bedrosian - Belmont MA, US
Camille L. Bedrosian - Belmont MA, US
International Classification:
A61K 31/522, A61K 31/4965, A61K 31/454, A61P 35/00
US Classification:
51425506, 51426332, 514323
Abstract:
Disclosed are methods for treating various cancers. Methods encompass the administration of an mTOR inhibitor in combination with a second drug selected from an ImiD, a PDE4 inhibitor, a p38 MAP kinase inhibitor, a xanthine anticytokine, a dual TACE/MMP inhibitor and a proteasome inhibitor.The methods are aimed at providing a desirable therapeutic window while maintaining prior, if not higher, dose levels of the mTOR inhibitor.
Capecitabine Combination Therapy
US Patent:
2009031, Dec 17, 2009
Filed:
Jun 4, 2007
Appl. No.:
12/227656
Inventors:
Luca Gianni - Milan, IT
Camille L. Bedrosian - Belmont MA, US
Camille L. Bedrosian - Belmont MA, US
International Classification:
A61K 39/395, A61P 35/00, A61K 31/506
US Classification:
4241331, 514274
Abstract:
The invention provides the use of a combination of an mTOR inhibitor and capecitabine in the treatment of cancer.
Treatment Method
US Patent:
2008008, Apr 3, 2008
Filed:
Sep 30, 2005
Appl. No.:
11/663940
Inventors:
Camille L. Bedrosian - Belmont MA, US
International Classification:
A61K 31/33, A61K 9/00, A61P 43/00
US Classification:
424400, 514183
Abstract:
A method for treating AML is disclosed which comprises administering an mTOR inhibitor to a patient in need thereof.
Combination Therapy
US Patent:
2010026, Oct 21, 2010
Filed:
Aug 1, 2007
Appl. No.:
12/309665
Inventors:
George D. Demetri - Brookline MA, US
Stephen T. Sonis - Wayland MA, US
Camille L. Bedrosian - Belmont MA, US
Stephen T. Sonis - Wayland MA, US
Camille L. Bedrosian - Belmont MA, US
International Classification:
A61K 39/395, A61P 35/00, A61P 35/02
US Classification:
4241341, 4241331, 4241421
Abstract:
Disclosed are methods for treating various cancers. Methods encompass the administration of a first drug such as AP23573, temsirolimus or everolimus in combination with a second drug selected from Remicade, Humira, Enbrel, Raptiva, Abatacept, Actermra, Cimzia or anakinra.The methods are aimed at providing a desirable therapeutic window while maintaining prior, if not higher, dose levels of the first drug.
Therapeutic Methods
US Patent:
2007018, Aug 9, 2007
Filed:
Nov 14, 2006
Appl. No.:
11/598850
Inventors:
Camille Bedrosian - Belmont MA, US
International Classification:
A61K 31/4353
US Classification:
514299000
Abstract:
Disclosed are methods for treating a patient with an mTOR inhibitor such as AP23573, sirolimus, temsirolimus, everolimus, etc.